文档详情

摩根大通 2015年上海医药投资价值研究报告.pdf

发布:2015-08-04约字共39页下载文档
文本预览下载声明
North America Equity Research 29 November 2010 Initiation Overweight ShangPharma Corp. SHP, SHP US Price: $11.72 Rise of the Chinese CRO; Initiate at Overweight Price Target: $16.00 We are initiating coverage on ShangPharma Corporation (SHP) with an Life Science Tools Diagnostics Overweight rating and December 2011 price target of $16. The second-largest AC Tycho W. Peterson biopharmaceutical RD outsourcing partner based in China, ShangPharma has (1-212) 622-6568 built an impressive franchise since being founded in 2002 and today provides over tycho.peterson@ 200 customers with a range of services in the drug discovery and development J.P. Morgan Securities LLC chain, including discovery chemistry and biology, preclinical development, and active pharm
显示全部
相似文档